SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New lupus injection enters first human safety tests
Disease control OngoingThis early-stage study tests a new drug called SG301, given as an injection under the skin, to see if it is safe for people with systemic lupus erythematosus (SLE). The study first gives a single dose to healthy volunteers, then multiple doses to lupus patients. Researchers will …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New lupus drug KK4277 enters first human safety trials
Disease control OngoingThis early-stage study is testing a new drug called KK4277 to see if it is safe for people with lupus. The trial first gives a single dose to healthy men, then repeated doses to people with systemic or cutaneous lupus. The main goal is to check for side effects and measure how th…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Promising autoimmune therapy trial pulled before it even started
Disease control TerminatedThis study was designed to test a new treatment for people with autoimmune diseases like lupus, scleroderma, and myositis. It combined a specially engineered immune cell product (CLBR001) with a targeted antibody drug (SWI019), with or without a preparatory chemotherapy step. How…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New lupus drug shows promise in Long-Term safety trial
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who finished earlier studies will continue taking the drug for up to 3 years, along with their usual treatments. The goal is to see how safe it is and how well it …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 10, 2026 13:29 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses donor immune cells engineered to target and destroy faulty immune cells that attack the body. The goal is to find a safe dose …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Adicet Therapeutics • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC
-
Experimental CAR T-Cell therapy targets lupus in small trial
Disease control OngoingThis early study tests a new treatment called Descartes-08 for people with systemic lupus erythematosus (SLE), an autoimmune disease. The therapy uses a patient's own immune cells, modified to attack lupus-related cells. The main goals are to check safety and see if it can reduce…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated May 29, 2026 14:16 UTC